Added: Jun 30, 2011 2:32 pm
THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR QUOTE. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND QUOTES WILL NOT BE REQUESTED.
The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisitions (OA), on behalf of the National Human Genome Research Institute (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to DiscoverX Corporation, 42501 Albrae Street, Suite 100, Fremont, CA 94538-3142 to provide the following to the NIH Chemical Genomics Center (NCGC):
- PathHunter Detection Kits
- PathHunter D2 CHO K-1 Bulk Frozen Cells Vial
This request is for 3 different assays that will be used to identify modulators of D2 dopamine receptor signaling through β-arrestin-2 (NIH MLPCN R21 Grant # NS0676421-01). The overall goal of this project is to identify chemical probes that selectively modify D2 DAR signaling through β-arrestin-mediated pathways as opposed to G protein-mediated pathways. The idea that ligands can selectively modulate different signaling pathways of the same receptor is referred to as functional selectivity. Three different assays are needed to identify three distinct kinds of modulators: agonists, antagonists and potentiators.
The sole source determination is based on the fact that the Principal Investigator and NCGC tested different assay formats to measure selective signaling of the D2 dopamine receptor through -arrestin (work described in the R21 grant application). The only assay format that met the standard assay robustness criteria for high-throughput screening (HTS) was the DiscoverX assay. The DiscoverX D2 dopamine assay for -arrestin signal uses the DiscoverX PathHunter technology. In this assay system, β-Arrestin is fused to an N-terminal deletion mutant of β-gal (termed the enzyme acceptor of EA) the GPCR of interest is fused to a smaller (42 amino acids), weakly complementing fragment termed ProLink. In cells that stably express these fusion proteins, ligand stimulation results in the interaction of β-Arrestin and the ProLink-tagged GPCR, forcing the complementation of the two β-gal fragments and resulting in the formation of a functional enzyme that converts substrate to detectable signal. NCGC has done extensive work (described in Fast Track application submitted from the R21 grant) to miniaturize the assay to 1536-well format and demonstrated that it produces robust data using the HTS capabilities at NCGC by doing pilot screens with small compound collections. The current D2 DiscoverX assay is ready for HTS at NCGC. At this moment, there is no alternative assay available to measure D2 dopamine -arrestin signaling that would allow NCGC to screen of a large collection of compounds (>350,000).
The delivery point is the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), Bethesda, Maryland.
The North American Industry Classification System (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology), with a small business size standard of 500 employees. This acquisition is being conducted under FAR Part 13, Simplified Acquisition Procedures, therefore the requirements of FAR Part 6, Competitive Requirements, are not applicable and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2005-52 (June 30, 2011).
Interested parties may identify their interest and capabilities in response to this synopsis by July 5, 2011 at 3:00pm Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurements.
Inquiries to this announcement, referencing synopsis number NHLBI-CSB-(HG)-2011-235-JML, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisitions, COAC Services Branch, 6701 Rockledge Drive, Room 6151, Bethesda, Maryland 20892-7902, Attention: Jonathan Lear. Responses may be submitted electronically to firstname.lastname@example.org. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.